Tuberculous hepatitis in renal transplant recipients following alemtuzumab induction therapy. Issue 1 (26th December 2012)

• Record Type: Journal Article
• Authors: Bosch, W.; Poowanawittayakom, N.; Chaikriangkrai, K.; Mendez, J.; Hellinger, W.C.; Gonwa, T.A.; Krishna, M.; Pungpapong, S.
• Is Part Of: Transplant infectious disease. Volume 15:Issue 1(2013)
• Page Start: E33
• Page End: E39
• Publication Date: 2012-12-26
• Subjects: Transplantation of organs, tissues, etc -- Complications -- Periodicals; Communicable diseases -- Periodicals; Infection -- Periodicals; 617.01
• DOI: 10.1111/tid.12048
• Languages: English
• ISSNs: 1398-2273

Abstract

<abstract abstract-type="main" id="tid12048-abs-0001"> <title>Abstract</title> <p> <italic>Mycobacterium tuberculosis</italic> infection is one of many opportunistic infections in renal transplant recipients, arising either from reactivation of latent infection or <italic>de novo</italic> infection, occasionally donor derived. <italic>M. tuberculosis</italic> hepatitis has never been reported in patients who have received alemtuzumab as part of their renal transplant management. We describe 2 patients who underwent deceased‐donor renal transplantation following alemtuzumab induction therapy and presented with a febrile syndrome, subsequently diagnosed as tuberculous hepatitis, one with disseminated disease. Both responded well to treatment without significant side effects, resulting in excellent graft function. The importance of chemoprophylaxis should be emphasized to minimize the risk of developing active tuberculosis in patients with latent tuberculosis infection undergoing solid organ transplantation.</p> </abstract>